Summit Therapeutics Inc. Repayments of Related Party Debt
Summit Therapeutics Inc. (SMMT) reported Repayments of Related Party Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfRelatedPartyDebt · last filed 2026-02-23
- Summit Therapeutics Inc. repayments of related party debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. repayments of related party debt for the quarter ending 2025-09-30 was -$75.50M, a 200.00% decline year-over-year.
- Summit Therapeutics Inc. repayments of related party debt for the quarter ending 2025-06-30 was $0.00.
- Summit Therapeutics Inc. repayments of related party debt for the quarter ending 2025-03-31 was $75.50M.
- Summit Therapeutics Inc. repayments of related party debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Summit Therapeutics Inc. repayments of related party debt for fiscal 2024 was $100.00M, a 305.09% increase from fiscal 2023.
- Summit Therapeutics Inc. repayments of related party debt for fiscal 2023 was $24.69M, a 1.26% decline from fiscal 2022.
- Summit Therapeutics Inc. repayments of related party debt for fiscal 2022 was $25.00M, a 77.27% decline from fiscal 2021.
| Period end | Repayments of Related Party Debt | Repayments of Related Party Debt 3 month | Repayments of Related Party Debt 6 month | Repayments of Related Party Debt 9 month | Repayments of Related Party Debt 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$75.50M derived: sum of 2 quarters · filed 2026-02-23 | -$75.50M derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2025-09-30 | -$75.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | -$75.50M derived: sum of 2 quarters · filed 2025-10-20 | $0.00 10-Q · filed 2025-10-20 | $75.50M derived: sum of 4 quarters · filed 2025-10-20 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $75.50M 10-Q · filed 2025-08-11 | $151.00M derived: sum of 3 quarters · filed 2025-08-11 | $226.50M derived: sum of 4 quarters · filed 2025-10-20 | |
| 2025-03-31 | $75.50M 10-Q · filed 2025-05-01 | $151.00M derived: sum of 2 quarters · filed 2025-05-01 | $226.50M derived: sum of 3 quarters · filed 2025-10-20 | $226.50M derived: sum of 4 quarters · filed 2025-10-20 | |
| 2024-12-31 | $75.50M 10-K · filed 2025-02-24 | $151.00M derived: sum of 2 quarters · filed 2025-10-20 | $151.00M derived: sum of 3 quarters · filed 2025-10-20 | $100.00M 10-K · filed 2026-02-23 | |
| 2024-10-01 | $24.50M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $75.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $75.50M derived: sum of 2 quarters · filed 2025-10-20 | $75.50M 10-Q · filed 2025-10-20 | $75.50M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-09-16 | $75.50M 10-K · filed 2026-02-23 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $24.69M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $24.69M 10-Q · filed 2024-10-30 | $24.69M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $24.69M 10-Q · filed 2024-08-06 | $24.69M derived: sum of 3 quarters · filed 2025-02-24 | $49.69M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | $24.69M 10-Q · filed 2024-05-01 | $24.69M derived: sum of 2 quarters · filed 2025-02-24 | $49.69M derived: sum of 3 quarters · filed 2025-02-24 | $49.69M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $25.00M derived: sum of 2 quarters · filed 2025-02-24 | $25.00M derived: sum of 3 quarters · filed 2025-02-24 | $25.00M 10-K · filed 2025-02-24 | |
| 2022-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $25.00M derived: sum of 2 quarters · filed 2023-11-07 | $25.00M 10-Q · filed 2023-11-07 | $25.00M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-08-09 | $0.00 derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $110.00M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $110.00M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $110.00M 10-Q · filed 2022-08-11 | ||||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $0.00 derived: sum of 2 quarters · filed 2022-12-21 | $0.00 10-K/A · filed 2022-12-21 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |